{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:49:56Z","timestamp":1769737796805,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T00:00:00Z","timestamp":1469491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.atherosclerosis.2016.07.007","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T09:59:45Z","timestamp":1468663185000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice"],"prefix":"10.1016","volume":"252","author":[{"given":"Alberico L.","family":"Catapano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Lautsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Tokg\u00f6zoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Ferrieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Horack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Brudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baishali","family":"Ambegaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anselm K.","family":"Gitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib1","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.07.007_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.5551\/jat.31237","article-title":"Cascade screening in familial hypercholesterolemia: advancing forward","volume":"22","author":"Santos","year":"2015","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc Med."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib5","series-title":"The metabolic and molecular basis of inherited disease","first-page":"2863","author":"Goldstein","year":"2001"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacl.2013.12.005","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia\u2013full report","volume":"8","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin. Vasc. Med."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib12","first-page":"59","article-title":"News from the European Atherosclerosis Society Congress: FH initiative","volume":"22","author":"Cardio Staff","year":"2015","journal-title":"Br. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"13s","key":"10.1016\/j.atherosclerosis.2016.07.007_bib14","first-page":"2016","article-title":"Persistent high distance to recommended LDL-cholesterol-targets despite chronic statin treatment: results of DYSIS","volume":"67","author":"Gitt","year":"1934","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib15","series-title":"FDA Drug Safety Communication: New Restrictions, Contraindications, and Dose Limitations for Zocor (Simvastatin) to Reduce the Risk of Muscle Injury","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib16","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib17","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199906243402501","article-title":"Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels","volume":"340","author":"Lichtenstein","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.1992.03480070077035","article-title":"Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice","volume":"267","author":"Henkin","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1210\/edrv-6-4-590","article-title":"Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states","volume":"6","author":"Heimberg","year":"1985","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib20","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","article-title":"Cardiovascular remodelling in coronary artery disease and heart failure","volume":"383","author":"Heusch","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vph.2015.03.008","article-title":"New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory","volume":"71","author":"Packard","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/eurheartj\/eht232","article-title":"Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study","volume":"35","author":"McConnachie","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"de Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib26","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib28","unstructured":"Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER). http:\/\/clinicaltrials.gov\/show\/NCT01764633 2015 Available from: URL: ClinicalTrials.gov."},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib29","series-title":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome during Treatment with Alirocumab SAR236553 (REGN727)","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2016.07.007_bib30","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.07.007_bib31","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.atherosclerosis.2014.05.889","article-title":"Variability of LDL-C response with different doses of simvastatin, atorvastatin and rosuvastatin: results from voyager","volume":"235","author":"Karlson","year":"2015","journal-title":"Atheroscler. Suppl."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016303069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016303069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:55:14Z","timestamp":1761191714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016303069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":31,"alternative-id":["S0021915016303069"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.007","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}